The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Open accessAbstract
Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A mechanism for the suppression of homologous recombination in G1 cells
Orthwein, A., Noordermeer, S. M., Wilson, M. D., Landry, S., Enchev, R. I., Sherker, A., Munro, M., Pinder, J., Salsman, J., Dellaire, G., et al. (2015) · Nature · doi:10.1038/nature16142 · Cited by 471 · cited 2×
“BRCA1 interacts with the PALB2–BRCA2 complex and promotes its localization to DSBs, enabling PALB2–BRCA2 to load RAD51 onto ssDNA (Sy et al. 2009; Zhang et al. 2009; Orthwein et al. 2015).”
RetractedTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 2×
“…include up-regulation of efflux pump (Rottenberg et al. 2008), loss of PARP1 (Pettitt et al. 2013), restoration of the BRCA1/2 reading frame (Edwards et al. 2008; Sakai et al. 2008), loss of KU (Patel et al. 2011; Bunting et al. 2012; Choi et al. 2016), altered DNA end processing (Wang et…”
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Schlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936 · cited 1×
“Independently of their HR functions, BRCA1 and BRCA2 are required for the protection of stalled replication forks (Schlacher et al. 2011, 2012; Ying et al. 2012).”
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Self-citationEx vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Self-citationATR prohibits replication catastrophe by preventing global exhaustion of RPA
Toledo, L. I., Altmeyer, M., Rask, M.-B., Lukas, C., Larsen, D. H., Povlsen, L. K., Bekker-Jensen, S., Mailand, N., Bartek, J., & Lukas, J. (2013) · Cell · doi:10.1016/j.cell.2013.10.043 · Cited by 911 · cited 2×
“ATRi may reactivate MRE11-mediated fork degradation by inducing DSBs (Toledo et al. 2013).”
Escribano-Díaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.001 · Cited by 900
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869 · cited 3×
“Among their many functions, BRCA1 and BRCA2 proteins are important for homologous recombination (HR) and protection of stalled DNA replication forks (Prakash et al. 2015).”
InfluentialSearching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845 · cited 1×
“Olaparib and VE-821 displayed a greater synergy in SYr12 than olaparib and cisplatin according to the Bliss model (Yadav et al. 2015).”
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 2×
“In cell-free assays, inhibitors of ATM (ATMi: KU55933), ATR (ATRi: VE-821), and DNA-PK (DNA-PKi: NU7026) all have IC50s in the 10 – 100 nM range (Hollick et al. 2003; Hickson et al. 2004; Reaper et al. 2011).”
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Sy, S. M. H., Huen, M. S. Y., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811159106 · Cited by 614
Chapman, J. R., Barral, P., Vannier, J.-B., Borel, V., Steger, M., Tomas-Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., & Boulton, S. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.002 · Cited by 606
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 603
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., & Yu, X. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.018 · Cited by 562
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449
Analysis of protein dynamics at active, stalled, and collapsed replication forks
Sirbu, B. M., Couch, F. B., Feigerle, J. T., Bhaskara, S., Hiebert, S. W., & Cortez, D. (2011) · Genes & Development · doi:10.1101/gad.2053211 · Cited by 440
Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W., & Elledge, S. J. (2012) · Nature Cell Biology · doi:10.1038/ncb2426 · Cited by 433
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 401
Self-citationAn update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 373
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Callen, E., Di Virgilio, M., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H.-T., Faryabi, R. B., Polato, F., Santos, M., Starnes, L. M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.023 · Cited by 346
Self-citationMre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 346
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Boersma, V., Moatti, N., Segura-Bayona, S., Peuscher, M. H., van der Torre, J., Wevers, B. A., Orthwein, A., Durocher, D., & Jacobs, J. J. L. (2015) · Nature · doi:10.1038/nature14216 · Cited by 304
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
Feng, L., Fong, K.-W., Wang, J., Wang, W., & Chen, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457440 · Cited by 272
Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0186 · Cited by 269
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair
Bunting, S. F., Callén, E., Kozak, M. L., Kim, J. M., Wong, N., López-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.015 · Cited by 252
Self-citationMaréchal, A., Li, J.-M., Ji, X. Y., Wu, C.-S., Yazinski, S. A., Nguyen, H. D., Liu, S., Jiménez, A. E., Jin, J., & Zou, L. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.002 · Cited by 249
Self-citationPrevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 202
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Coupling of Homologous Recombination and the Checkpoint by ATR
Buisson, R., Niraj, J., Rodrigue, A., Ho, C. K., Kreuzer, J., Foo, T. K., Hardy, E. J.-L., Dellaire, G., Haas, W., Xia, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.007 · Cited by 181
Self-citationA high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Lord, C. J., McDonald, S., Swift, S., Turner, N. C., & Ashworth, A. (2008) · DNA Repair · doi:10.1016/j.dnarep.2008.08.014 · Cited by 178
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 174
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
XRCC3 and Rad51 Modulate Replication Fork Progression on Damaged Vertebrate Chromosomes
Henry-Mowatt, J., Jackson, D., Masson, J.-Y., Johnson, P. A., Clements, P. M., Benson, F. E., Thompson, L. H., Takeda, S., West, S. C., & Caldecott, K. W. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00132-1 · Cited by 164
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 149
DelloRusso, C., Welcsh, P. L., Wang, W., Garcia, R. L., King, M., & Swisher, E. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0234 · Cited by 147
Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart
Somyajit, K., Saxena, S., Babu, S., Mishra, A., & Nagaraju, G. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv880 · Cited by 138
PTIP associates with Artemis to dictate DNA repair pathway choice
Wang, J., Asaithamby, A., Löbrich, M., Li, Y., Chen, D. J., Chen, J., & Gong, Z. (2014) · Genes & Development · doi:10.1101/gad.252478.114 · Cited by 134
Wang, H., Wang, H., Powell, S. N., Iliakis, G., & Wang, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1289 · Cited by 130
A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma
Xing, D., & Oršulić, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1495 · Cited by 127
Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery
Murphy, A., Fitzgerald, M., Ro, T., Kim, J. H., Rabinowitsch, A. I., Chowdhury, D., Schildkraut, C. L., & Borowiec, J. A. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201404111 · Cited by 119
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106
Hollick, J. J., Golding, B. T., Hardcastle, I. R., Martin, N. M. B., Richardson, C. J., Rigoreau, L. J. M., Smith, G. C. M., & Griffin, R. J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00652-8 · Cited by 102
Infante, J. R., Tabernero, J. M., Burris, H. A., Macarulla, T. M., Martin, M., Liu, Y., Jessen, K., Koczon, E., Rommel, C., Klein, P., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-5588 · Cited by 94
Mechanisms of Resistance to PARP Inhibitors—Three and Counting
Fojo, T., & Bates, S. E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0514 · Cited by 79
Ogiwara, H., Ui, A., Shiotani, B., Zou, L., Yasui, A., & Kohno, T. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt240 · Cited by 78
Self-citationSomyajit, K., Basavaraju, S., Scully, R., & Nagaraju, G. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01521-12 · Cited by 71
ATM/ATR‐mediated phosphorylation of PALB2 promotes RAD51 function
Ahlskog, J. K., Larsen, B. D., Achanta, K., & Sørensen, C. S. (2016) · EMBO Reports · doi:10.15252/embr.201541455 · Cited by 65
Kurfürstová, D., Bártková, J., Vrtěl, R., Mičková, A., Burdová, A., Majera, D., Mistrík, M., Král, M., Santer, F. R., Bouchal, J., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.02.005 · Cited by 57
Hendrickson, B. C., Judkins, T., Ward, B. D., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20189 · Cited by 56
Huehls, A. M., Wagner, J. M., Huntoon, C. J., & Karnitz, L. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080614 · Cited by 37
Chen, S., Wang, G., Niu, X., Zhao, J., Tan, W., Wang, H., Zhao, L., & Ge, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.010 · Cited by 31
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
Abusanad, A. M., Wang, Y., Hasheminasab, F., Panasci, J., Noë, A., Rosca, L., Davidson, D. L., Amrein, L., Sharif-Askari, B., Aloyz, R. S., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00147 · Cited by 20
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“Yazinski and colleagues further demonstrated that PARPinhibitor resistant, BRCA1-deficient cells become dependent on ATR for survival [81].”
BackgroundPARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Metadata
- Authors
- Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., Ramaswamy, S., Benes, C. H., Haber, D. A., Maheswaran, S., Birrer, M. J., & Zou, L.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-01
- Volume
- 31
- Issue
- 3
- Pages
- 318-332
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2594301310
- Cited by
- 395
- References
- 80
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.